Powered by OpenAIRE graph
Found an issue? Give us feedback

USC

University of Santiago de Compostela
Funder
Top 100 values are shown in the filters
Results number
arrow_drop_down
489 Projects, page 1 of 98
  • Funder: European Commission Project Code: 101109331
    Funder Contribution: 181,153 EUR

    The forces governing the nano-biointeractions are essential to understand the biological behaviour and pharmacokinetics of the nanostructures. So far, these understandings have been limited to nanoparticles. However, it should be noted that the NPs´ chemical synthetic methods render non-homogeneous dispersions, even when low polydispersity is reached. In addition, the modification of NPs with a specific number of ligands is still challenging and there is no agreement about the most effective configuration or number of ligands to achieve efficient targeting in vivo. The programmability of the DNA-nanostructures (origamis) allows the synthesis of predictable and controllable sizes and shapes with almost atomic precision. In addition, the origamis can also be designed to include additional molecules, with high accuracy on the valency and the orientation. Thus, this technology offers a powerful tool to study and understand the biological behaviour of objects at the nanoscale since precise control over the size, shape and attachment of molecules can be achieved when other methods are unable to. Based on the structural organization and spatial distribution of natural and specific bionanoparticles, such as viruses, this project will exploit the atomic programmability of origamis to design a library of DNA nanostructures inspired on viral particles. The biomolecular corona will be studied to understand its impact on origamis´ biodistribution, a topic still not studied yet. Finally, the cell response will be evaluated in terms of targeting and immune response. These results will help to a better understanding of the mechanism between nano-structures and living systems and to formulate guidelines to synthesize more efficient nanomedicines. Overall, this project will allow me to carry out a 2-year project independently, growing towards a mature, professional and independent researcher in the DNA nanotechnology field, reinforcing my expertise on the nanomedicine field.

    more_vert
  • Funder: Fundação para a Ciência e a Tecnologia, I.P. Project Code: SFRH/BD/64692/2009
    more_vert
  • Funder: European Commission Project Code: 101146373
    Funder Contribution: 328,722 EUR

    The global commitment to protect 30% of the oceans by 2030 faces several key challenges in preserving nature without exacerbating existing coastal resource conflicts. As ocean protection is rapidly increasing to halt biodiversity loss, we urgently need to understand why people value nature to better address these conflicts. The REVALSEA project will provide a novel theoretical approach and empirical evidence to quantify, predict, and integrate into marine conservation the diverse ways people express why they value their relationship with nature, i.e., relational values, in coastal systems. Relational values (RVs) emerge as a keystone in conservation efforts breaking with the traditional exclusively material valuation of nature and opening a new opportunity to adopt more inclusive and socially relevant strategies for biodiversity conservation. This aspect is rarely explored in marine systems, even when its consideration in conservation is critical to increase equity and reduce resource conflicts. Addressing RVs in marine conservation policies needs overcoming several intergenerational, methodological, and operational challenges. First, it must consider the intergenerational gap between what matters for those who influence decision-making (adults) and for those who have the potential to generate social-ecological changes (youth). Second, it requires the use of innovative interdisciplinary social-ecological research that integrates multidimensional datasets and uses novel machine learning technology to maximise data efficiency while minimising economic costs of data collection and analysis. Finally, it needs transdisciplinary cooperation with stakeholders and decision makers to co-generate specific recommendations for integrating RVs in conservation policies. REVALSEA will focus on the small-scale fisher’s community in Spain as a case study to address all these challenges and develop a cutting-edge and globally scalable approach in other socio-cultural contexts.

    more_vert
  • Funder: European Commission Project Code: 101113110
    Overall Budget: 2,498,960 EURFunder Contribution: 2,498,960 EUR

    TraffikGene-Tx: Targeted and Dynamic RNA Peptide Vehicles -Unmet Clinical Need and Problem Rare and complex genetic diseases lead to significant disability, death and associated cost burdens for society. Complex genetic diseases include cardiovascular diseases (CVD) and cancer, the two leading causes of death in the EU and up to 36 million Europeans suffer from rare genetic diseases. Nucleic acid therapeutics (NATs) represent a potential treatment, but they are hampered by the “delivery problem.” Systemically administered naked RNA is quickly degraded by endonucleases, can provoke adverse immune reactions and has off-target toxicity. Viral and lipid nanoparticle (LNP) delivery vectors have toxic side-effects and are difficult to produce and target. -The Solution TraffikGene´s RNA delivery platform is: Safe: biodegradable, non-immunogenic peptide carriers that cleave to avoid the detergent toxicity of LNPs. Targetable: beyond the liver, to the spleen, lungs and heart with excellent delivery to the cytosol. Scalable: Production is automated, simple and cheap. TraffikGene combines modular design with high-throughput screening which will feed into AI-enhanced SAR-based predictive vehicle design. This will accelerate and de-risk NAT drug development. -The Project TraffikGene will capitalize on the current breakthroughs in healthcare represented by NATs. RNA therapeutics (mRNA, saRNA, siRNA, lncRNA, miRNA) are now emerging driven by the success of mRNA vaccines and TraffikGene will deliver them to the tissues where they are needed. We aim to break new ground in the field of RNA, validate our delivery vehicles and start developing our pipeline to advance to the preclinical trial stage with therapeutic RNAs. We aim to launch our company of customised peptide carriers for any RNA medicine with a proprietary flagship RNA-based immunotherapy. Our products will bring many promising NATs to the market, and help millions of patients, while reducing health care costs.

    more_vert
  • Funder: Fundação para a Ciência e a Tecnologia, I.P. Project Code: SFRH/BD/8562/2002
    more_vert

Do the share buttons not appear? Please make sure, any blocking addon is disabled, and then reload the page.

Content report
No reports available
Funder report
No option selected
arrow_drop_down

Do you wish to download a CSV file? Note that this process may take a while.

There was an error in csv downloading. Please try again later.